Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020

被引：0
|
作者：
Luka Flegar
Smita George Thoduka
Damiano Librizzi
Markus Luster
Aristeidis Zacharis
Hendrik Heers
Nicole Eisenmenger
Hojjat Ahmadzadehfar
Matthias Eiber
Wolfgang Weber
Christer Groeben
Johannes Huber
机构：
[1] Philipps-University Marburg,Department of Urology
[2] Philipps-University Marburg,Department of Nuclear Medicine
[3] Reimbursement Institute,Department of Nuclear Medicine
[4] Klinikum Westfalen GmbH,Department of Nuclear Medicine
[5] Technische Universität Munich,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2023年 / 50卷
关键词：
Prostate cancer; mCRPC; Lutetium-; PSMA (; Lu-PSMA); Radioligand therapy; Health services research; Trends;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2188 / 2195
页数：7
相关论文
共 50 条
  • [21] 177Lutetium PSMA radioligand therapy in patients with metastatic castration resistant prostatic cancer; assessment of response, clinical evaluation, toxicity
    Rathore, H. R.
    Bhat, G.
    Aland, P.
    Kannor, C.
    Kale, C.
    Parab, A.
    Chaudhuri, P.
    Lele, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S404 - S405
  • [22] Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
    Mehrens, Dirk
    Kramer, Kristina K. M.
    Unterrainer, Lena M.
    Beyer, Leonie
    Bartenstein, Peter
    Froelich, Matthias F.
    Tollens, Fabian
    Ricke, Jens
    Ruebenthaler, Johannes
    Schmidt-Hegemann, Nina-Sophie
    Herlemann, Annika
    Unterrainer, Marcus
    Kunz, Wolfgang G.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (01): : 43 - +
  • [23] Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Sahoo, Ranjit Kumar
    Dwivedi, Sada Nand
    Bal, Chandrasekhar
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2019, 213 (02) : 275 - 285
  • [24] The Auckland experience with Lutetium-177 prostate-specific membrane antigen (177LU-PSMA-617) in advanced, metastatic castration-resistant prostate cancer (mCRPC): 2018-2020
    Hitchen, Nadia
    Waldron, Nick
    Lawrence, Nicola
    Fu, Simon
    Jacobs, Carmel
    Hanning, Fritha
    Lim, Remy
    Fong, Peter
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 67 - 67
  • [25] Outcome and prognostic predictors of Lu177-PSMA radioligand therapy in metastatic castration-resistant prostate cancer (Asian population study)
    Chua, W.
    Lam, W.
    Tong, A.
    Sultana, R.
    Kua, S.
    Kanesvaran, R.
    Wong, A.
    Tay, K.
    Cheng, T.
    Ng, D.
    Thang, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S400 - S401
  • [26] Outcomes and prognostic predictors of Lu-177 PSMA radioligand therapy in metastatic castration-resistant prostate cancer (Asian Population Study)
    Chua, Wei Ming
    Lam, Winnie Wing-Chuen
    Tong, Aaron Kian-Ti
    Sultana, Rehena
    Kua, Sandra Mei Yu
    Kanesvaran, Ravindran
    Wong, Alvin Seng Cheong
    Tay, Kae Jack
    Cheng, Tai Jit Lenith
    Ng, David Chee Eng
    Thang, Sue Ping
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 (05) : 572 - 581
  • [27] Therapy-related Myeloid Neoplasms Following Lutetium-177 [177Lu]Lu-PSMA Therapy in patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series
    Eifer, M.
    Sutherland, D. E. K.
    Goncalves, I.
    Buteau, J. P.
    Akhurst, T.
    Alipour, R.
    Au, L.
    Azad, A. A.
    Cardin, A.
    Chen, D.
    Emmerson, B.
    Emmett, L.
    Jewell, K.
    Kong, G.
    Kashyap, R.
    Kostos, L.
    Kumar, A. S. Ravi
    Kwan, E. M.
    Macfarlane, L.
    Medhurst, E.
    Saghebi, J.
    Sandhu, S.
    Tran, B.
    Wyatt, A. W.
    Hofman, M. S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S677 - S677
  • [28] 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sanli, Yasemin
    Simsek, Duygu Has
    Sanli, Oner
    Subramaniam, Rathan M.
    Kendi, Ayse Tuba
    BIOMEDICINES, 2021, 9 (04)
  • [29] 177Lu-PSMA-I&T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer:FirstClinical trialin Asia
    Bu, Ting
    Zhang, Pengjun
    Zang, Shiming
    Zhang, Lulu
    Wang, Feng
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [30] Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer
    Rahbar, Kambiz
    Bode, Axel
    Weckesser, Matthias
    Avramovic, Nemanja
    Claesener, Michael
    Stegger, Lars
    Boegemann, Martin
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (07) : 522 - 528
12345